Given the ability of CD19@NP/17-DMAG to stimulate T-cell responses and induce leukemia cell apoptosis, we hypothesized that combining it with the broad-spectrum TKI ponatinib could maximize efficacy 49-52. Here, CD19 is linked to leukemia.